Carl Zeiss Meditec AG (Carl Zeiss Meditec), a subsidiary of Carl Zeiss AG, manufactures ophthalmic diagnostic and therapeutic products, including examination and surgical microscopes, diagnostic systems, laser surgery equipment, and intraocular lenses. The company operates branch offices, including production, sales, services, and R&D sites, and authorized sales and service facilities in the Americas, Europe, and Asia-Pacific.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Carl Zeiss Meditec is focused on expanding its product range and improving existing products, aiming to establish new gold standards in medical diagnostics and therapy. The company's R&D initiatives focus on enhancing customer workflows through integrated solutions and improving clinical results. Collaboration with customers from the early stages of product development is a key element of the company's R&D work. The company also focuses on examining new technological concepts, developing new products and platforms, and digital networking of systems to enhance diagnostic and treatment efficiency. The R&D unit of Carl Zeiss Meditec collaborates closely with customers to manage the company's R&D activities, focusing on examining new technological concepts, developing existing product portfolios, and integrating digital solutions to improve treatment outcomes. In FY2024, the company incurred EUR343.1 million on R&D, which stood at 16.6% of the company’s total revenue, and declined 1.8% YoY. As of September 2024, Carl Zeiss Meditec currently owns more than 900 patent families globally and has 197 registered brand families.